苏交科(300284) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 1,408,948,300.10, representing a decline of 18.16% year-on-year[9] - Net profit attributable to shareholders was CNY 203,222,070.06, an increase of 10.98% compared to the same period last year[9] - Basic earnings per share for the reporting period were CNY 0.2092, reflecting a growth of 10.98% year-on-year[9] - The weighted average return on net assets was 4.61%, a decrease of 0.14% compared to the previous year[9] - The net cash flow from operating activities was negative at CNY -584,518,828.40 for the year-to-date[9] - Total operating revenue for the current period was ¥1,408,948,300.10, a decrease of 18.2% compared to ¥1,721,579,453.19 in the previous period[63] - Net profit for the current period was ¥201,971,476.56, an increase of 7.4% compared to ¥187,892,815.71 in the previous period[66] - The total profit for the current period is CNY 522,895,149.89, up from CNY 471,200,146.54, reflecting a growth of 10.9%[83] - Operating income for the current period is CNY 1,945,856,581.10, a decrease of 2.0% from CNY 1,985,618,341.29 in the previous period[88] - The company reported a decrease in operating costs to CNY 1,254,767,821.87 from CNY 1,320,769,200.57, representing a reduction of 5.0%[88] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,488[14] - The largest shareholder, Fu Guanhua, held 21.01% of the shares, amounting to 204,126,710 shares[14] - The company did not engage in any repurchase transactions during the reporting period[16] - The total number of restricted shares at the beginning of the period was 318,343,196, with 10,305,200 shares released during the period, resulting in 308,037,996 restricted shares at the end of the period[24] - The largest shareholder, 符冠华, holds 158,696,782 shares, which remains unchanged during the period[18] - The second largest shareholder, 王军华, holds 107,673,652 shares, also unchanged during the period[18] - The company has a high executive lock-up policy, with 25% of shares unlocking annually for certain executives[18] - The total number of shares held by the top 10 shareholders remains stable, indicating strong insider confidence[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 11,937,535,526.73, a decrease of 2.58% compared to the end of the previous year[9] - The company's total assets as of September 30, 2019, were ¥11,937,535,526.73, down from ¥12,253,979,388.78, a decrease of approximately 2.57%[52] - Total liabilities decreased to ¥7,837,606,658.89 from ¥8,707,956,594.71, reflecting a reduction of about 10%[49] - The company's equity attributable to shareholders increased to ¥4,522,949,193.80 from ¥4,242,573,289.98, showing an increase of about 6.6%[52] - The company's short-term borrowings decreased to ¥2,425,321,244.42 from ¥2,483,473,182.20, a decline of approximately 2.3%[46] - The long-term borrowings increased to ¥593,295,480.00 from ¥372,400,000.00, indicating a rise of about 59.1%[49] Cash Flow and Investments - Cash and cash equivalents decreased by 43.91% due to increased operational investment[29] - The company's cash and cash equivalents decreased to ¥1,487,017,172.37 from ¥2,651,218,445.78, representing a decline of about 43.5%[43] - The cash flow from operating activities decreased to CNY 2,899,061,954.30 from CNY 4,121,073,875.35, a decline of 29.6%[96] - Investment cash outflow reached CNY 244,714,087.60, compared to CNY 300,780,499.55 in the previous year[102] - Net cash flow from investing activities was CNY -223,871,918.77, an improvement from CNY -259,130,479.29 year-over-year[102] - Financing cash inflow totaled CNY 2,559,941,202.90, up from CNY 2,409,490,736.39 in the previous period[102] - Financing cash outflow was CNY 3,299,515,732.72, compared to CNY 1,888,599,112.49 in the prior year[102] - The ending balance of cash and cash equivalents was CNY 981,340,786.68, down from CNY 648,604,027.61 in the previous period[102] Research and Development - Research and development expenses for the current period were ¥53,557,516.44, an increase of 34.7% from ¥39,785,550.84 in the previous period[63] - Research and development expenses increased to CNY 73,210,000.16, up from CNY 67,908,626.33, indicating a rise of 7.0%[90] Other Financial Metrics - Other comprehensive income decreased by 300.16% primarily due to exchange rate fluctuations[29] - Financial expenses decreased by 36.40% mainly due to foreign exchange gains[29] - The company reported a significant credit impairment loss of ¥64,012,773.56 during the current period[74] - The company experienced a significant increase in financial expenses, rising to CNY 63,413,786.31 from CNY 17,789,119.50, which is an increase of 256.0%[90] - The third quarter report was not audited, which may affect the reliability of the financial data presented[132]